← Back to Search

Other

Moringa Powder Acceptability in Healthy Adults

N/A
Waitlist Available
Led By Susana Matias, PhD
Research Sponsored by University of California, Berkeley
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing Moringa leaf powder added to food or drinks in people without a specific disease. The goal is to find a safe and acceptable dose by testing different amounts. Moringa may help with blood sugar and cholesterol due to its nutrients and anti-inflammatory properties. Moringa oleifera leaves have been traditionally used in India as a hypocholesterolemic agent and have shown significant cholesterol-lowering effects in various studies.

Who is the study for?
This trial is for UC Berkeley staff aged 18-65 who can communicate in English or Spanish. It's designed to see how they feel about taking different amounts of Moringa powder every day.
What is being tested?
The study tests the acceptability of three doses of Moringa powder taken daily by healthy adults. Participants are randomly assigned to one of the dose groups: low, medium, or high.
What are the potential side effects?
Potential side effects from consuming Moringa powder may include digestive discomfort, allergic reactions, or changes in appetite but will vary based on individual tolerance and dose.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability
Consumption
Side effects
Secondary study objectives
Daily dose consumed
Other study objectives
Change in skin carotenoids
Taste
Texture
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Moringa Powder - Medium DoseExperimental Treatment1 Intervention
Group A
Group II: Moringa Powder - Low DoseExperimental Treatment1 Intervention
Group C
Group III: Moringa Powder - High DoseExperimental Treatment1 Intervention
Group B

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Tuberculosis (TB) include antibiotics such as isoniazid, rifampin, ethambutol, and pyrazinamide. These antibiotics work by targeting the Mycobacterium tuberculosis bacteria in different ways: isoniazid inhibits the synthesis of mycolic acids, essential components of the bacterial cell wall; rifampin inhibits RNA synthesis by targeting bacterial RNA polymerase; ethambutol disrupts cell wall formation by inhibiting arabinosyl transferases; and pyrazinamide disrupts membrane transport and energy production. These mechanisms are crucial for TB patients as they directly kill or inhibit the growth of the bacteria, thereby reducing the bacterial load and preventing the spread of the disease. Nutritional supplementation, such as Moringa powder, which has anti-inflammatory and antioxidant effects, may support TB treatment by enhancing the immune response and reducing inflammation, potentially improving overall patient outcomes.
Nutraceutical potential of mushroom bioactive metabolites and their food functionality.Black Cumin (<i>Nigella sativa</i> L.): A Comprehensive Review on Phytochemistry, Health Benefits, Molecular Pharmacology, and Safety.B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine.

Find a Location

Who is running the clinical trial?

University of California, BerkeleyLead Sponsor
186 Previous Clinical Trials
640,696 Total Patients Enrolled
University of California, DavisOTHER
939 Previous Clinical Trials
4,739,697 Total Patients Enrolled
1 Trials studying Tuberculosis
500 Patients Enrolled for Tuberculosis
Susana Matias, PhDPrincipal InvestigatorUniversity of California, Berkeley

Media Library

Moringa Powder (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05861076 — N/A
Tuberculosis Research Study Groups: Moringa Powder - Low Dose, Moringa Powder - Medium Dose, Moringa Powder - High Dose
Tuberculosis Clinical Trial 2023: Moringa Powder Highlights & Side Effects. Trial Name: NCT05861076 — N/A
Moringa Powder (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05861076 — N/A
~18 spots leftby Nov 2025